Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05403502 · ClinicalTrials.gov registry record · NA
Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes
A NA study, sponsored by Tandem Diabetes Care.
- Completed
- Registry status
- NA
- Development phase
- 183
- Enrollment target
NCT05403502 is a NA study that has completed, run by Tandem Diabetes Care. The registered enrollment target is 183 participants.
The verdict
NCT05403502, a NA study, has completed, sponsored by Tandem Diabetes Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 183 participants
- Enrollment target
Study Summary
Prospective, multi-center, single-arm study in adults and children ages 6 to 80 with type 1 diabetes to evaluate the safety of Lyumjev with Control-IQ technology to achieve labeling updates for Lyumjev and the t:slim X2 insulin pump.
Interventions
- DEVICE t:slim X2 insulin pump with Control-IQ technology 1.5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2023-08-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05403502
The ClinicalTrials.gov registry entry for NCT05403502 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tandem Diabetes Care, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which t:slim X2 insulin pump with Control-IQ technology 1.5 is the first listed.
NCT05403502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05403502 about?
NCT05403502 is a clinical study titled "Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes". Prospective, multi-center, single-arm study in adults and children ages 6 to 80 with type 1 diabetes to evaluate the safety of Lyumjev with Control-IQ technology to achieve labeling updates for Lyumjev and the t:slim X2 insulin pump.
What is the current status of trial NCT05403502?
This trial is currently completed. It is a NA study. The enrollment target is 183 participants. The study started on 2022-08-31. Estimated completion is 2023-08-02.
What interventions are being tested in trial NCT05403502?
The interventions under investigation include: t:slim X2 insulin pump with Control-IQ technology 1.5 (DEVICE).
Who is sponsoring clinical trial NCT05403502?
This trial is sponsored by Tandem Diabetes Care, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.